Cannabinoid Derived Pharmaceutical Market Size, Share & Trends Analysis Report By Product (Natural (Plant-derived), Synthetic Cannabinoid), By Molecule Type (Cannabinoid Receptor Type 1 (CB1), Cannabinoid Receptor Type 2 (CB2), Others), By Disease Indication, By Route Of Administration, By Application, By Formulation, By Cannabinoid  Type, By Region, And Segment Forecasts, 2025-2034

Report Id: 1042 Pages: 180 Last Updated: 05 November 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Cannabinoid Derived Pharmaceutical Market Segmentation

Global Cannabinoid Derived Pharmaceutical Market, by Products, 2025-2034 (Value US$ Mn)

·       Natural (Plant-Derived Cannabinoids)

o   Epidiolex

o   Sativex

o   Other Plant-Derived Pipeline Products

·       B. Synthetic Cannabinoids

o   Marinol

o   Syndros

o   Cesamet

o   Other Synthetic Pipeline Products  

Cannabinoid Derived Pharmaceutical Market

Global Cannabinoid Derived Pharmaceutical Market, by Molecule Type, 2025-2034 (Value US$ Mn)

·       Cannabinoid Receptor Type 1

·       Cannabinoid Receptor Type 2

·       Dual / Non-Selective Receptor Modulators

·       Others

Global Cannabinoid Derived Pharmaceutical Market, by By Source / Origin 

·       Plant-Derived Cannabinoids             

·       Synthetic Cannabinoids       

Global Cannabinoid Derived Pharmaceutical Market, by Disease Indication, 2025-2034 (Value US$ Mn)

  • Alzheimer's Disease
  • Autism
  • Cancer
  • Chronic Pain
  • Epilepsy
  • Migraine
  • Multiple Sclerosis
  • Schizophrenia
  • Others

Global Cannabinoid Derived Pharmaceutical Market, by Formulation

·       Oral     

·       Topical             

·       Oral Sprays    

·       Inhalation / Vaporization      

·       Others

Global Cannabinoid Derived Pharmaceutical Market, by Cannabinoid Type

·       CBD-Based Pharmaceuticals          

·       THC-Based Pharmaceuticals           

·       Synthetic Cannabinoids       

·       Minor Cannabinoids & Derivatives 

·       Cannabinoid Receptor Modulators / Analogues   

Global Cannabinoid Derived Pharmaceutical Market, By Distribution Channel   

·       Hospital Pharmacies

·       Retail Pharmacies / Drug Stores     

  •      Online Pharmacies / Specialty Distribution

Global Cannabinoid Derived Pharmaceutical Market, By Therapeutic Indication / Application 

·       Neurological Disorders         

·       Chronic Pain 

·       Oncology / Cancer Supportive Care            

·       Psychiatric & Behavioral Disorders

·       Inflammatory & Autoimmune Diseases     

Global Cannabinoid Derived Pharmaceutical Market, by Region, 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Cannabinoid Derived Pharmaceutical Market, by Country,

  • The U.S.
  • Canada

Europe Cannabinoid Derived Pharmaceutical Market, by Country,

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Cannabinoid Derived Pharmaceutical Market, by Country,

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Cannabinoid Derived Pharmaceutical Market, by Country,

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Cannabinoid Derived Pharmaceutical Market, by Country,

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa
 
 
 
 

Chapter 1.    Methodology and Scope

1.1.    Research Methodology
1.2.    Research Scope & Assumptions

Chapter 2.    Executive Summary

Chapter 3.    Global Cannabinoid Derived Pharmaceutical Market Snapshot

Chapter 4.    Global Cannabinoid Derived Pharmaceutical Market Variables, Trends & Scope

4.1.    Market Segmentation & Scope
4.2.    Drivers
4.3.    Challenges
4.4.    Trends 
4.5.    Investment and Funding Analysis 
4.6.    Porter's Five Forces Analysis
4.7.    Incremental Opportunity Analysis (US$ MN), 2024-2034 
4.8.    Global Cannabinoid Derived Pharmaceutical Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
4.9.    Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10.    Use/impact of AI on Cannabinoid Derived Pharmaceutical Market Industry Trends 

Chapter 5.    Cannabinoid Derived Pharmaceutical Market Segmentation 1: By Products, Estimates & Trend Analysis

5.1.    Market Share by Products, 2024 & 2034

5.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Products:

5.2.1.    Natural (Plant-Derived Cannabinoids)

5.2.1.1.    Epidiolex
5.2.1.2.    Sativex
5.2.1.3.    Other Pipeline Products

5.2.2.    Synthetic Cannabinoid

5.2.2.1.    Marinol (dronabinol)
5.2.2.2.    Syndros (dronabinol)
5.2.2.3.    Cesamet (nabilone)
5.2.2.4.    Other Pipeline Products 

Chapter 6.    Cannabinoid Derived Pharmaceutical Market Segmentation 2: By Molecule Type, Estimates & Trend Analysis

6.1.    Market Share by Molecule Type, 2024 & 2034
6.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:

6.2.1.    Cannabinoid Receptor Type 1 (CB1)
6.2.2.    Cannabinoid Receptor Type 2 (CB2)
6.2.3.    Dual / Non-Selective Receptor Modulators 

Chapter 7.    Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Cannabinoid Type, Estimates & Trend Analysis

7.1.    Market Share by Cannabinoid Type, 2024 & 2034
7.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Cannabinoid Type:

7.2.1.    CBD-Based Pharmaceuticals 
7.2.2.    THC-Based Pharmaceuticals 
7.2.3.    Synthetic Cannabinoids 
7.2.4.    Minor Cannabinoids & Derivatives 
7.2.5.    Cannabinoid Receptor Modulators / Analogues 

Chapter 8.    Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Therapeutic Indication / Application, Estimates & Trend Analysis

8.1.    Market Share by Therapeutic Indication / Application, 2024 & 2034
8.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Indication / Application:

8.2.1.    Neurological Disorders    
8.2.2.    Chronic Pain
8.2.3.    Oncology / Cancer Supportive Care
8.2.4.    Psychiatric & Behavioral Disorders

Chapter 9.    Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Route of Administration / Formulation, Estimates & Trend Analysis

9.1.    Market Share by Route of Administration / Formulation, 2024 & 2034
9.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration / Formulation:

9.2.1.    Oral
9.2.2.    Topical
9.2.3.    Oral Spray
9.2.4.    Inhalation

Chapter 10.    Inflammatory & Autoimmune Diseases

Chapter 11.    Cannabinoid Derived Pharmaceutical Market Segmentation 5: Regional Estimates & Trend Analysis

11.1.    Global Cannabinoid Derived Pharmaceutical Market, Regional Snapshot 2024 & 2034

11.2.    North America

11.2.1.    North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.2.1.1.    US
11.2.1.2.    Canada

11.2.2.    North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.2.3.    North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.2.4.    North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.2.5.    North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.2.6.    North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034

11.3.    Europe

11.3.1.    Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.3.1.1.    Germany
11.3.1.2.    U.K.
11.3.1.3.    France
11.3.1.4.    Italy
11.3.1.5.    Spain
11.3.1.6.    Rest of Europe

11.3.2.    Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.3.3.    Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.3.4.    Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.3.5.    Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.3.6.    Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034

11.4.    Asia Pacific

11.4.1.    Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.4.1.1.    India 
11.4.1.2.    China
11.4.1.3.    Japan
11.4.1.4.    Australia
11.4.1.5.    South Korea
11.4.1.6.    Hong Kong
11.4.1.7.    Southeast Asia
11.4.1.8.    Rest of Asia Pacific

11.4.2.    Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.4.3.    Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.4.4.    Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.4.5.    Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.4.6.    Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034

11.5.    Latin America

11.5.1.    Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.5.1.1.    Brazil
11.5.1.2.    Mexico
11.5.1.3.    Rest of Latin America

11.5.2.    Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.5.3.    Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.5.4.    Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.5.5.    Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.5.6.    Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034

11.6.    Middle East & Africa 

11.6.1.    Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

11.6.1.1.    GCC Countries
11.6.1.2.    Israel
11.6.1.3.    South Africa
11.6.1.4.    Rest of Middle East and Africa

11.6.2.    Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
11.6.3.    Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.6.4.    Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2021-2034
11.6.5.    North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Indication / Application, 2021-2034
11.6.6.    Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration / Formulation, 2021-2034

Chapter 12.    Competitive Landscape

12.1.    Major Mergers and Acquisitions/Strategic Alliances
12.2.    Company Profiles

12.2.1.    Jazz Pharmaceuticals plc (via GW Pharmaceuticals — Epidiolex, Sativex)
12.2.2.    AbbVie Inc.
12.2.3.    Bausch Health Companies Inc.
12.2.4.    Botanix Pharmaceuticals Ltd.
12.2.5.    Kannalife Sciences Inc.
12.2.6.    Aphios Pharma LLC
12.2.7.    Tilray Brands, Inc. (Tilray Medical)
12.2.8.    Panaxia Pharmaceutical Industries Ltd.
12.2.9.    Enveric Biosciences, Inc.
12.2.10.    ZYUS Life Sciences Inc.
12.2.11.    Skye Bioscience, Inc.
12.2.12.    Teon Therapeutics, Inc.
12.2.13.    CURE Pharmaceutical Corporation
12.2.14.    CB Therapeutics Inc.
12.2.15.    Ananda Pharma plc
12.2.16.    MIRA Pharmaceuticals, Inc.
12.2.17.    Anebulo Pharmaceuticals, Inc.
12.2.18.    Cronos Group Inc.
12.2.19.    Aurora Cannabis Inc.
12.2.20.    Canopy Growth Corporation
12.2.21.    Curaleaf Holdings, Inc.
12.2.22.    Trulieve Cannabis Corp.
12.2.23.    Green Thumb Industries Inc.
12.2.24.    Others
12.2.25.    Avecho Biotechnology Ltd.
12.2.26.    Other Prominent Players      

 

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5802
Security Code field cannot be blank!

Frequently Asked Questions

The key players of this market include Cara Therapeutics, Inc., Arena Pharmaceuticals, Cannabics Pharmaceuticals Inc., Echo Pharmaceuticals, GW Pharma

Cannabinoid Derived Pharmaceutical Market Size is valued at USD 12.6 Billion in 2024 and is predicted to reach USD 81.1 Billion by the year 2034

The Cannabinoid Derived Pharmaceutical Market is expected to grow at an 20.8% CAGR during the forecast period for 2025-2034.

Cannabinoid Derived Pharmaceutical market is segmented on the basis of By Product, By Molecule Type, By Disease Indication, by cannabinoid type, by formulation, By Application, By Source.

North American region is leading the Cannabinoid Derived Pharmaceutical market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying